Sale!

PRRT2 Gene Convulsions Familial Infantile with Paroxysmal Choreoathetosis Genetic Test

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The PRRT2 gene convulsions familial infantile with paroxysmal choreoathetosis genetic test is a specialized diagnostic tool used to identify mutations in the PRRT2 gene, which are linked to a rare neurological disorder. This condition is characterized by early-onset convulsions, typically seen in infants, and can evolve into paroxysmal choreoathetosis in later life, manifesting as sudden, involuntary movements. The test plays a crucial role in confirming the diagnosis, enabling early intervention and tailored management strategies for affected individuals.

Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves analyzing the patient’s DNA to detect abnormalities in the PRRT2 gene that are indicative of the disorder. The cost of the test is set at 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify the genetic variations associated with this condition. By opting for this test, families can gain valuable insights into the genetic underpinnings of the disorder, facilitating informed decisions about care and treatment options.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

PRRT2 Gene Convulsions familial infantile with paroxysmal choreoathetosis Genetic Test

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test Type: Neurological Disorders

Doctor: Neurologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for PRRT2 Gene Convulsions, familial infantile, with paroxysmal choreoathetosis NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with PRRT2 Gene Convulsions, familial infantile, with paroxysmal choreoathetosis.

Test Details

The PRRT2 gene is associated with a rare genetic disorder called familial infantile convulsions with paroxysmal choreoathetosis (ICCA). This disorder is characterized by recurrent episodes of seizures and involuntary movements, such as chorea and athetosis, which usually begin in infancy or early childhood.

NGS genetic testing for the PRRT2 gene can help diagnose ICCA and aid in genetic counseling for affected individuals and their families. The test involves sequencing the entire PRRT2 gene to identify any mutations or variants that may be responsible for the disorder.

Early diagnosis and management of ICCA can help prevent complications and improve the quality of life for affected individuals. Treatment may include antiepileptic medications to control seizures and physical therapy to manage movement disorders.

Test Name PRRT2 Gene Convulsions familial infantile with paroxysmal choreoathetosis Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for PRRT2 Gene Convulsions, familial infantile, with paroxysmal choreoathetosis NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with PRRT2 Gene Convulsions, familial infantile, with paroxysmal choreoathetosis
Test Details

The PRRT2 gene is associated with a rare genetic disorder called familial infantile convulsions with paroxysmal choreoathetosis (ICCA). This disorder is characterized by recurrent episodes of seizures and involuntary movements, such as chorea and athetosis, which usually begin in infancy or early childhood.

NGS genetic testing for the PRRT2 gene can help diagnose ICCA and aid in genetic counseling for affected individuals and their families. The test involves sequencing the entire PRRT2 gene to identify any mutations or variants that may be responsible for the disorder.

Early diagnosis and management of ICCA can help prevent complications and improve the quality of life for affected individuals. Treatment may include antiepileptic medications to control seizures and physical therapy to manage movement disorders.